Alethia Young

Alethia Young Recent News

Gilead Analyst Sees Catalyst Ahead In Data Readout For Potential Coronavirus Treatment
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Is Intercept Pharma's Updated Late-Stage NASH Data A Sell-The-News Event?
Cantor Fitzgerald Bumps Puma Biotechnology Price Target On Strong Nerlynx Sales
Analysts Laud Sarepta's 'Increasingly Active' Gene Therapy Clinical Development
Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish
Credit Suisse: Celgene Needs To Win Back Investor Trust
Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy
U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'
Credit Suisse Weighs In Ahead Of PTC Therapeutics' Thursday AdCom Panel For Translarna
A Veteran CEO Might Be Just What Sarepta Therapeutics Needed
C-Suite Shake Up: How Paul Clancy Jumping Ship Affects Alexion, Biogen
3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene
Is The FDA Panel Vote On Puma Biotech Likely To Lead To Actual Approval?
Analysts On Gilead: We Think They're Mobilizing For A Deal
Gilead Looking To Buy Incyte? It Makes Sense
Stay Of Court Injunction A Mild Positive For Regeneron
Credit Suisse Says Sarepta Shares Volatile, Still A Favorite Idea
Biogen's Spinraza Could Cost $125,000 Per Dose
Alexion Management On Internal Investigation: So Far, So Good
AC Immune Is An Alzheimer's Pure Play With A Lot On The Line

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved